Nusinersen in SMA 2 and 3 Risks vs benefits

被引:3
|
作者
Deymeer, Feza [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Neurol, Istanbul, Turkey
关键词
SHAM CONTROL;
D O I
10.1212/WNL.0000000000009919
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:151 / 152
页数:2
相关论文
共 50 条
  • [1] Nusinersen in SMA 2 and 3 Risks vs benefits (vol 95, pg 151, 2020)
    Nusinersen, Deymeer F.
    NEUROLOGY, 2020, 95 (21) : 987 - 987
  • [2] Benefits of nusinersen extend to later-onset SMA
    Heather Wood
    Nature Reviews Neurology, 2018, 14 : 196 - 196
  • [3] Benefits of nusinersen extend to later-onset SMA
    Wood, Heather
    NATURE REVIEWS NEUROLOGY, 2018, 14 (04) : 196 - 196
  • [4] Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients
    Wurster, Claudia D.
    Winter, Benedikt
    Wollinsky, Kurt
    Ludolph, Albert C.
    Uzelac, Zeljko
    Witzel, Simon
    Schocke, Michael
    Schneider, Ralf
    Kocak, Tugrul
    JOURNAL OF NEUROLOGY, 2019, 266 (01) : 183 - 194
  • [5] Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients
    Claudia D. Wurster
    Benedikt Winter
    Kurt Wollinsky
    Albert C. Ludolph
    Zeljko Uzelac
    Simon Witzel
    Michael Schocke
    Ralf Schneider
    Tugrul Kocak
    Journal of Neurology, 2019, 266 : 183 - 194
  • [6] Development of motor function in late vs early treatment with nusinersen for SMA type 1 and 2 patients
    Henriksson, I.
    Alberg, L.
    Kroksmark, A.
    Wahlgren, L.
    Tulinius, M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1486 - 1487
  • [7] FELBATOL - BENEFITS VS RISKS
    HIPP, KK
    FRISBIE, JA
    GILMARTIN, RC
    RAWLINGS, P
    EPILEPSIA, 1995, 36 : 334 - 334
  • [8] Nusinersen potentially effective in SMA
    Louise Adams
    Nature Reviews Neurology, 2017, 13 (2) : 66 - 66
  • [10] Compost: Benefits vs. Risks
    Michel, Fred
    COMPOST SCIENCE & UTILIZATION, 2010, 18 (03) : 137 - 137